{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:58:53Z","timestamp":1785131933678,"version":"3.55.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among 342 US infants with congenital cytomegalovirus treated with antivirals, 114 (33%) received ganciclovir (with or without valganciclovir) and 228 (67%) received valganciclovir only, for a median of 8 and 171 days, starting at a median of 15 and 45 days of life, respectively, with neutropenia diagnosed in 25% and 17%.<\/jats:p>","DOI":"10.1093\/jpids\/piac034","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:15:31Z","timestamp":1650482131000},"page":"379-382","source":"Crossref","is-referenced-by-count":18,"title":["Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States"],"prefix":"10.1093","volume":"11","author":[{"given":"Jessica","family":"Leung","sequence":"first","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Grosse","sequence":"additional","affiliation":[{"name":"National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Yockey","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-4786","authenticated-orcid":false,"given":"Tatiana M","family":"Lanzieri","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"2022083017083102500_CIT0001","article-title":"Cytomegalovirus infection.","volume-title":"Red Book: 2021 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics.","year":"2021","edition":"32"},{"key":"2022083017083102500_CIT0002","doi-asserted-by":"crossref","DOI":"10.1002\/lary.30027","article-title":"The effect of (val)ganciclovir on hearing in congenital cytomegalovirus: a systematic review.","author":"De Cuyper","year":"2022","journal-title":"Laryngoscope"},{"key":"2022083017083102500_CIT0003","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease.","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"2022083017083102500_CIT0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-3476(94)70327-2","article-title":"Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience.","volume":"124","author":"Nigro","year":"1994","journal-title":"J Pediatr"},{"key":"2022083017083102500_CIT0005","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piab133","article-title":"Antiviral therapy and its long-term impact on hearing loss caused by congenital cytomegalovirus: much remains to be learned!","author":"Schleiss","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2022083017083102500_CIT0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"2022083017083102500_CIT0007","author":"Demmler-Harrison","year":"2021"},{"key":"2022083017083102500_CIT0008","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022083017083102500_CIT0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2022.03.042","article-title":"Changes in valganciclovir use among infants with congenital CMV diagnosis in the United States, 2009-2015 and 2016-2019.","author":"Leung","year":"2022","journal-title":"J Pediatr"},{"key":"2022083017083102500_CIT0010","author":"ClinicalTrials.gov.","year":"2021"},{"key":"2022083017083102500_CIT0011","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"2022083017083102500_CIT0012","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/03007995.2021.2006536","article-title":"Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection.","volume":"38","author":"Campione","year":"2021","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/11\/8\/379\/45626467\/piac034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/11\/8\/379\/45626467\/piac034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T17:09:18Z","timestamp":1661879358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/11\/8\/379\/6582741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,9]]},"published-print":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piac034","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,9]]}}}